Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

1. WO2005006958 - MODULATION DE L'EXPRESSION DE CEACAM1

Numéro de publication WO/2005/006958
Date de publication 27.01.2005
N° de la demande internationale PCT/US2004/022384
Date du dépôt international 12.07.2004
CIB
A61K 48/00 2006.01
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
KPRÉPARATIONS À USAGE MÉDICAL, DENTAIRE OU POUR LA TOILETTE
48Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C07H 21/04 2006.01
CCHIMIE; MÉTALLURGIE
07CHIMIE ORGANIQUE
HSUCRES; LEURS DÉRIVÉS; NUCLÉOSIDES; NUCLÉOTIDES; ACIDES NUCLÉIQUES
21Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques
04avec le désoxyribosyle comme radical saccharide
CPC
C12N 15/1138
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
1138against receptors or cell surface proteins
C12N 2310/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
10Type of nucleic acid
11Antisense
C12N 2310/14
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
10Type of nucleic acid
14interfering N.A.
C12N 2310/315
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
30Chemical structure
31of the backbone
315Phosphorothioates
C12N 2310/321
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
30Chemical structure
32of the sugar
3212'-O-R Modification
C12N 2310/3341
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
30Chemical structure
33of the base
334Modified C
33415-Methylcytosine
Déposants
  • ISIS PHARMACEUTICALS, INC. [US/US]; 2292 Faraday Avenue Carlsbad, CA 92008, US (AllExceptUS)
  • BENNETT, C., Frank [US/US]; US (UsOnly)
  • DOBIE, Kenneth, W. [GB/US]; US (UsOnly)
  • JAIN, Ravi [US/US]; US (UsOnly)
Inventeurs
  • BENNETT, C., Frank; US
  • DOBIE, Kenneth, W.; US
  • JAIN, Ravi; US
Mandataires
  • LEGAARD, Paul, K.; Cozen O'Connor 1900 Market Street Philadelphia, PA 19103, US
Données relatives à la priorité
60/486,65212.07.2003US
Langue de publication anglais (EN)
Langue de dépôt anglais (EN)
États désignés
Titre
(EN) MODULATION OF CEACAM1 EXPRESSION
(FR) MODULATION DE L'EXPRESSION DE CEACAM1
Abrégé
(EN)
Compounds, compositions and methods are provided for modulating the expression of CEACAM1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding CEACAM1 Methods of using these compounds for modulation of CEACAM1 expression and for diagnosis and treatment of disease associated with expression of CEACAM1 are provided.
(FR)
L'invention concerne des composés, compositions et procédés permettant de moduler l'expression de CEACAM1. Ces compositions comprennent des oligonucléotides, ciblés sur un acide nucléique codant CEACAM1. L'invention concerne également des procédés d'utilisation de ces composés pour la modulation de l'expression de CEACAM1 et pour le diagnostic et le traitement de maladies associées à l'expression de CEACAM1.
Dernières données bibliographiques dont dispose le Bureau international